title: Lanthanide labeling of a potent protease activated receptor-2 agonist for time-resolved fluorescence analysis.
abstract: Protease activated receptor-2 (PAR(2)) is one of four G-protein coupled receptors (GPCRs) that can be activated by exogenous or endogenous proteases, which cleave the extracellular amino-terminus to expose a tethered ligand and subsequent G-protein signaling. Alternatively, PAR(2) can be activated by peptide or peptidomimetic ligands derived from the sequence of the natural tethered ligand. Screening of novel ligands that directly bind to PAR(2) to agonize or antagonize the receptor has been hindered by the lack of a sensitive, high-throughput, affinity binding assay. In this report, we describe the synthesis and use of a modified PAR(2) peptidomimetic agonist, 2-furoyl-LIGRLO-(diethylenetriaminepentaacetic acid)-NH(2) (2-f-LIGRLO-dtpa), designed for lanthanide-based time-resolved fluorescence screening. We first demonstrate that 2-f-LIGRLO-dtpa is a potent and specific PAR(2) agonist across a full spectrum of in vitro assays. We then show that 2-f-LIGRLO-dtpa can be utilized in an affinity binding assay to evaluate the ligand-receptor interactions between known high potency peptidomimetic agonists (2-furoyl-LIGRLO-NH(2), 2-f-LIGRLO; 2-aminothiazol-4-yl-LIGRL-NH(2), 2-at-LIGRL; 6-aminonicotinyl-LIGRL-NH(2), 6-an-LIGRL) and PAR(2). A separate N-terminal peptidomimetic modification (3-indoleacetyl-LIGRL-NH(2), 3-ia-LIGRL) that does not activate PAR(2) signaling was used as a negative control. All three peptidomimetic agonists demonstrated sigmoidal competitive binding curves, with the more potent agonists (2-f-LIGRLO and 2-at-LIGRL) displaying increased competition. In contrast, the control peptide (3-ia-LIGRL) displayed limited competition for PAR(2) binding. In summary, we have developed a europium-containing PAR(2) agonist that can be used in a highly sensitive affinity binding assay to screen novel PAR(2) ligands in a high-throughput format. This ligand can serve as a critical tool in the screening and development of PAR(2) ligands.
authors.affiliation: Department of Physiology, Arizona Health Sciences Center, 1501 North Campbell Avenue, Tucson, AZ 85724-5030, USA.
authors.forename: Justin
authors.initials: J
authors.lastname: Hoffman
authors.forename: Andrea N
authors.initials: AN
authors.lastname: Flynn
authors.forename: Dipti V
authors.initials: DV
authors.lastname: Tillu
authors.forename: Zhenyu
authors.initials: Z
authors.lastname: Zhang
authors.forename: Renata
authors.initials: R
authors.lastname: Patek
authors.forename: Theodore J
authors.initials: TJ
authors.lastname: Price
authors.forename: Josef
authors.initials: J
authors.lastname: Vagner
authors.forename: Scott
authors.initials: S
authors.lastname: Boitano
mesh_terms: D000818:Animals; D001667:Binding, Competitive; D002460:Cell Line; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D005063:Europium / Q000737:chemistry*; D006801:Humans; D009842:Oligopeptides / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology*; D004369:Pentetic Acid / Q000737:chemistry; D051381:Rats; D044464:Receptor, PAR-2 / Q000819:agonists* / Q000378:metabolism; D013050:Spectrometry, Fluorescence; D013194:Staining and Labeling; D013997:Time Factors
chemical_list: C487404:2-furoyl-LIGRLO-amide; D009842:Oligopeptides; D044464:Receptor, PAR-2; D005063:Europium; D004369:Pentetic Acid